مباشر

Endpoints NewsDriven by GLP-1s, pharma’s relationship with consumers is starting to change Clinical OMICsImpact of Current Genetic Testing on Cancer Survivor Treatment BioPharma DiveAfter raising $800M, Parabilis seeks an IPO to pursue ‘undruggable’ targets CellNociceptive innervation limits tertiary lymphoid structures to promote lung cancer CellGenome instability triggers intercellular DNA transfer between human cells FierceBiotechWith $30M launch, Oorja Bio breathes new life into South Korean fibrosis candidate FierceBiotechLilly pens $202M deal for preclinical DNA delivery biotech Engage as M&A streak continues BioPharma DiveBristol Myers deepens AI investment with Anthropic deal BioPharma DiveOorja, run by Acceleron veterans, launches to make new fibrosis drugs Endpoints NewsPfizer's next-gen pneumonia shot beats Prevnar 20; Relay targets $175M Clinical OMICsAnti-Inflammatory Drug Could Help Some People with Depression BioPharma DiveImmunovant’s potential autoimmune ‘blockbuster’; Wave’s RNA editing update

FierceBiotech ٢٠ مايو ٢٠٢٦

BMS taps Anthropic’s Claude for enterprise-wide AI adoption to speed R&D, global workflows

BMS is the latest large pharma company to make a major bet on AI, announcing a sweeping agreement with Anthropic to deploy its AI tool Claude as the “shared int...

BMS is the latest large pharma company to make a major bet on AI, announcing a sweeping agreement with Anthropic to deploy its AI tool Claude as the “shared intelligence platform” across the drugmaker’s global operations.